分析安羅替尼靶向治療聯(lián)合化療治療晚期乳腺癌的療效

打開(kāi)文本圖片集

【摘要】目的：分析晚期乳腺癌行安羅替尼靶向治療聯(lián)合化療的臨床療效。方法：截選2021年1月—2023年1月100例晚期乳腺癌患者，按照奇偶數(shù)法將其分為常規(guī)組（50例，化療）和聯(lián)合組（50例，安羅替尼靶向治療+化療），比較兩組血清腫瘤標(biāo)志物、癥狀積分、毒副反應(yīng)與治療效果。結(jié)果：治療后，聯(lián)合組CEA、CA153及CA125水平比常規(guī)組低（P

【關(guān)鍵詞】晚期乳腺癌；安羅替尼；靶向治療；化療

To analyze the efficacy of anlotinib targeted therapy combined with chemotherapy in the treatment of advanced breast cancer

REN Xiaoqiong

Pingliang Hospital of Traditional Chinese Medicine， Pingliang， Gansu 744000， China

【Abstract】Objective：To analyze the clinical efficacy of anlotinib targeted therapy combined with chemotherapy for advanced breast cancer.Methods：From January 2021 to January 2023，100 patients with advanced breast cancer were selected and divided into the conventional group （50 cases，chemotherapy） and the combined group （50 cases，anlotinib targeted therapy + chemotherapy） according to the odd-even method，and the serum tumor markers，symptom scores，toxic and side effects and therapeutic effects of the two groups were compared.Results：After treatment，the levels of CEA，CA153 and CA125 in the combined group were lower than those in the conventional group （P

【Key Words】Advanced breast cancer； Anlotinib； Targeted therapy； Chemotherapy

近年來(lái)，乳腺癌在全球范圍內(nèi)的發(fā)病率呈現(xiàn)出不斷增加的趨勢(shì)，成為女性最常見(jiàn)的惡性腫瘤之一[1]。（剩余4438字）